NervGen Pharma Corp.

In a recent podcast interview with Ira Pastor of Progress, Potential, and Possibilities, NervGen’s President & CEO, Mike Kelly, gave a deep dive into NervGen’s lead molecule, NVG-291, explained the benefits of conducting a clinical trial with a chronic SCI population, and described the primary and secondary endpoints of NervGen’s current Phase 1b/2a trial in traumatic spinal cord injury. Watch the full interview: https://lnkd.in/ekzJEZeA #SpinalCordInjury #SCI

NervGen’s President & CEO, Mike Kelly, recently spoke with Matthew Pillar on the Business of Biotech podcast about his career, what attracted him to NervGen, and how his approach to leadership enables him to build effective teams. Listen to the full interview: https://lnkd.in/etP-U8mm #SpinalCordInjury #SCI

Michael Kelly, NervGen’s President & CEO, was featured in an article from Jules ADAM of Labiotech.eu on the future of spinal cord injury treatment. Learn about NervGen’s approach to spinal cord injury and its lead molecule, NVG-291. Read the full article here: https://lnkd.in/ehreVbtP #SpinalCordInjury #SCI

NervGen today reported its financial results and operational updates for the third quarter of 2024.   Read the full release here: https://lnkd.in/eMWwqHJF

Mike Kelly, NervGen’s President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20 a.m. EST. Members of management will be available for one-on-one investor meetings during the conference. See here for the full news release:  https://lnkd.in/e9V68RQV #news

#DYK Our Phase 1b/2a clinical trial with NVG-291 in #SpinalCordInjury is enrolling subjects. Visit https://lnkd.in/eU2qURBt to learn more about the study, including eligibility requirements. #SCI #ClinicalTrials

Dr. Monica Perez of Shirley Ryan AbilityLab was featured on the Empowered Patient Podcast, hosted by Karen Jagoda. Dr. Perez provided an overview of the current standard of care for spinal cord injuries, why NVG-291, our lead drug candidate, has the potential to enable spinal cord repair, and our CONNECT SCI Study for #SpinalCordInjury. Learn more about the spinal cord injury study and its eligibility requirements at https://lnkd.in/eNCu_hSy Listen to the episode: https://lnkd.in/e5ZMHbpW   #SCI #clinicaltrials #science #pharmanews

#ICYMI - Dr. Monica Perez from Shirley Ryan AbilityLab spoke with Dina Bair from WGN-TV about our CONNECT SCI Study, which is exploring the potential of NVG-291 as a #spinalcordinjury treatment candidate.   “We hope that neurons grow and sprout to other connections so the connectivity will be stronger, therefore patients will be able to complete movement or restore movement.” – Dr. Monica Perez.   Learn more about eligibility requirements and enrollment: https://lnkd.in/eNCu_hSy.   Watch the video: https://lnkd.in/e3qEkj38     #SCI #clinicaltrials #science #pharmanews

#ICYMI - A TV segment on NBC Chicago featured our CONNECT SCI Study with Shirley Ryan AbilityLab. The discussion highlighted the importance of our NVG-291 research, as well as the impact of a potential new treatment for people living with spinal cord injury. Learn more about the spinal cord injury study and its eligibility requirements at https://lnkd.in/eNCu_hSy View NBC Chicago's segment https://lnkd.in/e7NZkjeV #SCI #clinicaltrials #science #pharmanews

NervGen’s CMO, Daniel Mikol MD, PhD, spoke with Greg Johnson of Radio Health Journal about NVG-291, NervGen’s lead drug candidate. NVG-291, which is currently being evaluated in a Phase 1b/2a clinical trial in spinal cord injury, has been shown to promote nervous system repair and improve functional recovery in preclinical animal models of nervous system damage. Listen to the interview here: https://lnkd.in/eRqtFKhd Visit www.connectscistudy.com to learn more about NervGen’s clinical trial for individuals living with spinal cord injury. #SCI #SpinalCordInjury